Zobrazeno 1 - 10
of 32
pro vyhledávání: '"Rachele Vaia"'
Autor:
Marco Caminati, MD, Alessandro Marcon, PhD, Rachele Vaia, MD, Gianenrico Senna, MD, Matteo Maule, MD, Pierpaolo Marchetti, MD, Jessica Miotti, MD, Giuseppe Argentino, MD, Francesco Blasi, MD, PhD, Giorgio W. Canonica, MD, Enrico M. Heffler, MD, PhD, Pierluigi Paggiaro, MD, Andrea Vianello, MD, PhD, Gabriella Guarnieri, MD, Luisa Brussino, MD PhD, S.S.D.D.U, Cecilia Calabrese, MD PhD, Gianna Camiciottoli, MD, Giovanna E. Carpagnano, MD PhD, Stefano Centanni, MD PhD, Angelo G. Corsico, MD PhD, Maria T. Costantino, MD, Claudia Crimi, MD PhD, Alice D'adda, MD, Simona D'alo, MD, Maria D'amato, MD PhD, Stefano Del Giacco, MD, Fabiano Di Marco, MD PhD, Nicola C. Facciolongo, MD, Manuela Latorre, MD PhD, Eustachio Nettis, MD, Eleonora Nucera, MD, Giovanni Passalacqua, MD, Girolamo Pelaia, MD, Laura Pini, MD PhD, Luisa Ricciardi, MD, Luca Richeldi, MD, Erminia Ridolo, MD PhD, Pierachille Santus, MD PhD, Nicola Scichilone, MD, Giulia Scioscia, MD PhD, Giuseppe Spadaro, MD, Antonio Spanevello, MD PhD, Paolo Tarsia, MD PhD
Publikováno v:
World Allergy Organization Journal, Vol 17, Iss 8, Pp 100941- (2024)
Background: Aging implies changes in terms of lung function, immune system, and respiratory and extra-respiratory comorbidities. Few studies have specifically addressed the relevance of age on severe asthma burden and control. We aimed to evaluate wh
Externí odkaz:
https://doaj.org/article/9826bfd798df48a19f3413facbb54880
Autor:
Marco Caminati, Matteo Maule, Roberto Benoni, Claudio Micheletto, Cristina Tecchio, Rachele Vaia, Lucia De Franceschi, Gabriella Guarnieri, Andrea Vianello, Gianenrico Senna
Publikováno v:
Orphanet Journal of Rare Diseases, Vol 18, Iss 1, Pp 1-6 (2023)
Abstract Mepolizumab at the dose of 300 mg/4 weeks has been recently approved as an add-on therapy for patients with uncontrolled hypereosinophilic syndrome (HES) without any identifiable non-hematologic secondary cause. According to the available re
Externí odkaz:
https://doaj.org/article/6ec1f65ac355458bad58e3b391114afa
Autor:
Marco Caminati, Matteo Maule, Roberto Benoni, Diego Bagnasco, Bianca Beghè, Fulvio Braido, Luisa Brussino, Paolo Cameli, Maria Giulia Candeliere, Giovanna Elisiana Carpagnano, Giulia Costanzo, Claudia Crimi, Mariella D’Amato, Stefano Del Giacco, Gabriella Guarnieri, Mona-Rita Yacoub, Claudio Micheletto, Stefania Nicola, Bianca Olivieri, Laura Pini, Michele Schiappoli, Rachele Vaia, Andrea Vianello, Dina Visca, Antonio Spanevello, Gianenrico Senna
Publikováno v:
Biomedicines, Vol 12, Iss 2, p 390 (2024)
Dupilumab is currently approved for the treatment of Type 2 severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP). Few studies have specifically reported on dupilumab efficacy on asthma outcomes as a primary objective in a real-life set
Externí odkaz:
https://doaj.org/article/3daaf0d88d9b489b9717495e5066b45f
Autor:
Gabriella Guarnieri, Marco Caminati, Alessia Achille, Rachele Vaia, Fulvia Chieco Bianchi, Gianenrico Senna, Andrea Vianello
Publikováno v:
Kompass Pneumologie. 10:159-162
Patienten mit schwerem Asthma haben ein erhöhtes Risiko für größere Komplikationen und müssen regelmäßig überwacht werden. Die COVID-19-Pandemie hat sich deutlich auf die Ressourcen des Gesundheitswesens ausgewirkt. Der telemedizinische Ansat
Autor:
Marco Caminati, Alessandro Marcon, Gabriella Guarnieri, Jessica Miotti, Diego Bagnasco, Giovanna Elisiana Carpagnano, Girolamo Pelaia, Rachele Vaia, Matteo Maule, Andrea Vianello, Gianenrico Senna
Overlapping eligibility to different biologics for severe asthma is still challenging, especially when addressing the same target. We aimed to characterize severe eosinophilic asthma patients according to their maintained or reduced response to mepol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e60ccac318a2505ae9b22596b0538ae
https://hdl.handle.net/11577/3474802
https://hdl.handle.net/11577/3474802
Autor:
Matteo Maule, Bianca Olivieri, Gabriella Guarnieri, Lucia De Franceschi, Nicola Martinelli, Rachele Vaia, Giuseppe Argentino, Andrea Vianello, Gianenrico Senna, Marco Caminati
Bronchial asthma is the most frequent inflammatory non-communicable condition affecting the airways worldwide. It is commonly associated with concomitant conditions, which substantially contribute to its burden, whether they involve the lung or other
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::86b0e131768c0dddd0959a931c21377f
https://hdl.handle.net/11562/1090247
https://hdl.handle.net/11562/1090247
Autor:
Marco Caminati, Gabriella Guarnieri, Pierluigi Paggiaro, Andrea Vianello, Ernesto Crisafulli, Rachele Vaia, Gianenrico Senna
Smoking habit is still fairly common among asthmatics. So far, the impact of smoke on severe asthma burden has not been specifically investigated. We aimed to estimate the frequency of smoking habit among severe asthma patients, their clinical featur
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a4e92d3987535c8337b9af896e49381
https://hdl.handle.net/11562/1083593
https://hdl.handle.net/11562/1083593
Autor:
Gabriella Guarnieri, Marco Caminati, Alessia Achille, Rachele Vaia, Fulvia Chieco Bianchi, Gianenrico Senna, Andrea Vianello
Severe asthma patients are at an increased risk of major complications and they need to be monitored regularly. The COVID-19 pandemic has notably impacted on the health care resources. The telemedicine approach applied to the follow-up of asthmatic p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5162fb60d9ad6ba4dfa76186051c477e
http://hdl.handle.net/11562/1074656
http://hdl.handle.net/11562/1074656
Publikováno v:
Biologics: Targets and Therapy. 13:89-95
In the last decades, the increasing evidence concerning inflammation mechanisms underlying severe eosinophilic asthma has highlighted new potential therapeutic targets and has paved the way to new selective biologic drugs. Understanding the mechanism